(NASDAQ: TLPH) Talphera's forecast annual revenue growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.41%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.37%.
Talphera's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast TLPH's revenue for 2026 to be $85,491,725, with the lowest TLPH revenue forecast at $85,491,725, and the highest TLPH revenue forecast at $85,491,725. On average, 1 Wall Street analysts forecast TLPH's revenue for 2027 to be $485,934,965, with the lowest TLPH revenue forecast at $485,934,965, and the highest TLPH revenue forecast at $485,934,965.
In 2028, TLPH is forecast to generate $1,020,600,213 in revenue, with the lowest revenue forecast at $1,020,600,213 and the highest revenue forecast at $1,020,600,213.